Citations

Showing 10 of 108104 citations.

Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.
Leroy, Karen , Jaïs, Jean‐Philippe , Ruminy, Philippe , Réyès, Cécile , Wright, George, Gascoyne, Randy D. , Staudt, Louis M. , Tilly, Hervé , Salles, Gilles , Molina, Thierry Jo , LYSA, Wright, George W. , Salles, Gilles A , Gentien, David , Scott, David W. , Rimsza, Lisa M. , Haïoun, Corinne , Gaulard, Philippe , Jardin, Fabrice , LYSA, Wright, George

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7547-7547

10.1200/jco.2016.34.15_suppl.7547 Get It

Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).
Nowakowski, Grzegorz S. , Chiappella, Annalisa , Spina, Michele , Gascoyne, Randy D. , Zhang, Lei , Flament, Jocelyne, Repici, Jacqueline, Conlin, Erin, Delissio, Krista, Witzig, Thomas E. , Vitolo, Umberto

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7538-7538

10.1200/jco.2016.34.15_suppl.7538 Get It

Treatment trends and outcomes in early-stage Hodgkin lymphoma in elderly: A National Cancer Data Base analysis.
Kanmanthareddy, Arun , Silberstein, Peter T., Goyal, Gaurav , Go, Ronald S. , Armitage, Jamés O.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7536-7536

10.1200/jco.2016.34.15_suppl.7536 Get It

Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study.
Younes, Anas , Santoro, Armando , Timmerman, John M. , Ansell, Stephen M. , Armand, Philippe , Fanale, Michelle A. , Ratanatharathorn, Voravit, Cohen, Jonathon B. , Kato, Kazunobu, Farsaci, Benedetto , Parker, Susan, Engert, Andreas , Santoro, Armando , Zinzani, Pier Luigi , Kuruvilla, John , Collins, Graham P. , Savage, Kerry J. , Trněný, Marek , Rodig, Scott J , Shipp, Margaret Ann

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7535-7535

10.1200/jco.2016.34.15_suppl.7535 Get It

Adverse event (AE) attribution in symptom intervention and cancer prevention trials.
Hillman, Shauna, Meyers, Jeffrey P., Loprinzi, Charles L. , Mandrekar, Sumithra J. , Le‐Rademacher, Jennifer , Limburg, Paul J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18111-e18111

10.1200/jco.2016.34.15_suppl.e18111 Get It

Patient-reported distress screening outcomes in breast cancer.
Smart, Bridget, Vallow, Laura A., Hollant, Laeticia, Single, Megan Paige, Gaines, Katherine , Habboush, Jacob, Biers, Heather, Day, Atiya, Tzou, Katherine S., May, Byron C. , Miller, Robert C.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18083-e18083

10.1200/jco.2016.34.15_suppl.e18083 Get It

The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.
Tefferi, Ayalew , Gangat, Naseema , Niederwieser, Dietger , Droogenbroeck, Jan Van, Baer, Maria R. , Cervantes, Francisco , Sirhan, Shireen , Langlois, Angélique, Wan, Ying , Sherman, Laurie, Dougherty, Souria, Feller, Faye, Odenike, Olatoyosi , Kiladjian, Jean‐Jacques , Hoffman, Ronald , Finazzi, Guido , Gotlib, Jason , Apperley, Jane F.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7079-TPS7079

10.1200/jco.2016.34.15_suppl.tps7079 Get It

INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME.
Garcia‐Manero, Guillermo , Al‐Kali, Aref , Baer, Maria R. , Collins, Robert H. , Shammo, Jamile M. , Raza, Azra , Silverman, Lewis R. , Azarnia, N., Fruchtman, Steven, Snyder, Barbara R, Fenaux, Pierre , Roboz, Gail J. , Platzbecker, Uwe , Kambhampati, Suman , Godley, Lucy A. , Santini, Valeria

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS7077-TPS7077

10.1200/jco.2016.34.15_suppl.tps7077 Get It

A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma.
Park, Steven I., Olajide, Oludamilola, Reddy, Nishitha , Richards, Kristy L. , Deal, Allison M. , Noe, Jeanne F., Shea, Thomas C., Ansell, Stephen M. , Budde, Lihua E. , Ghosh, Nilanjan , Deal, Allison

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7508-7508

10.1200/jco.2016.34.15_suppl.7508 Get It

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).
Evens, Andrew M. , Gascoyne, Randy D. , Quon, Andrew , Ansell, Stephen M. , Petrich, Adam M., Chang, Julie , O’Brien, Timothy E., Cheema, P. , Cescon, Terrence P., Sturtz, Keren , Evens, Andrew M , Hong, Fangxin , Habermann, Thomas M. , Advani, Ranjana H. , Witzig, Thomas E. , Wagner, Lynne I. , Kahl, Brad S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7507-7507

10.1200/jco.2016.34.15_suppl.7507 Get It